Wonbiogen Co Ltd
KOSDAQ:307280
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (2.5), the stock would be worth ₩2 549.98 (18% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.1 | ₩2 165 |
0%
|
| 3-Year Average | 2.5 | ₩2 549.98 |
+18%
|
| 5-Year Average | 2.9 | ₩2 954.05 |
+36%
|
| Industry Average | 5.7 | ₩5 745.58 |
+165%
|
| Country Average | 5.4 | ₩5 456.5 |
+152%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
W
|
Wonbiogen Co Ltd
KOSDAQ:307280
|
49.2B KRW | 2.1 | 7.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 23.4 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 6.3 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 8.1 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 5.2 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 6.6 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 8.9 | 43 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 5.2 | 18.4 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 16.7 | 41.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 5.7 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 9.1 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.7 |
| Median | 5.4 |
| 70th Percentile | 10.1 |
| Max | 19 609.2 |
Other Multiples
Wonbiogen Co Ltd
Glance View
Wonbiogen Co., Ltd. engages in the research and development of biocompatible medical materials. The company is headquartered in Gumi, Gyeongsangbuk-Do. The company went IPO on 2018-12-05. The firm provides medical products including dressing material used for lower leg ulcers, pressure ulcers and surgical wounds; dressing material for secretions absorption and wound area protection; fixing band for bandages, gauze, catheters, along with others.
